Abstract | BACKGROUND: METHODS: In order to evaluate the toxicity and efficacy of a new endocrine therapy for advanced/recurrent breast cancer, we ran a pilot study during the period from July 1994 to July 1996. RESULTS: Twenty-two patients with advanced/recurrent breast cancer were treated with chemoendocrine therapy consisting of cyclophosphamide (100 mg/body) p.o. daily for 14 days, with adriamycin (40 mg/m2) i.v. and 5-fluorouracil (500 mg/body) i.v. on day 1 (repeated every 3 weeks for 9 weeks) (CAF therapy), and high-dose toremifene (120 mg/body) p.o. daily. Of 20 evaluable patients, two showed complete response (10%), eight partial response (40%), six no change (30%) and four progressive disease (20%). The overall response rate was 50%, and the median duration of response was 69.5 days (28-133+ days). The major toxicities were drug-induced alopecia, gastrointestinal toxicity and hematological toxicity, but these were clinically well tolerated. No serious cardiac, liver or renal symptom was seen. CONCLUSIONS: Based on these results, we consider the addition of high-dose toremifene to the CAF therapy to be useful in the treatment of advanced and recurrent breast cancer.
|
Authors | T Tominaga, Y Nomura, J Uchino, K Hirata, M Kimura, M Yoshida, H Aoyama, H Kinoshita, H Koyama, Y Monden, S Takashima, M Ogawa |
Journal | Japanese journal of clinical oncology
(Jpn J Clin Oncol)
Vol. 28
Issue 4
Pg. 250-4
(Apr 1998)
ISSN: 0368-2811 [Print] England |
PMID | 9657010
(Publication Type: Journal Article)
|
Chemical References |
- Estrogen Antagonists
- Toremifene
- Doxorubicin
- Cyclophosphamide
- Fluorouracil
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Breast Neoplasms
(drug therapy)
- Cyclophosphamide
(administration & dosage)
- Doxorubicin
(administration & dosage)
- Drug Administration Schedule
- Estrogen Antagonists
(administration & dosage)
- Female
- Fluorouracil
(administration & dosage)
- Humans
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy)
- Toremifene
(administration & dosage)
|